The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
Herbert Hurwitz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Roche; Sanofi
Research Funding - Bristol-Myers Squibb; Genentech; Novartis; Pfizer; Roche; Sanofi
Nikhil Uppal
No relevant relationships to disclose
Stephanie Ann Wagner
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
J. Thaddeus Beck
Research Funding - Incyte
Seaborn Wade
No relevant relationships to disclose
John J. Nemunaitis
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
J. Marc Pipas
Research Funding - Incyte
Zev A. Wainberg
No relevant relationships to disclose
Robert Manges
Research Funding - Incyte
William M. Garrett
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Deborah S. Hunter
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Jason Clark
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Lance Leopold
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Richard S. Levy
Employment or Leadership Position - Incyte
Stock Ownership - Incyte
Victor Sandor
Employment or Leadership Position - Incyte
Stock Ownership - Incyte